Image

Gilead Sciences has submitted a new drug application to Japan’s Pharmaceutical and Medical Devices Agency (PMDA) for approval of its sofosbuvir for treatment of chronic hepatitis C virus (HCV) infection.

The data in the new drug application supports the use of sofosbuvir, a once-daily nucleotide analog polymerase inhibitor, with ribavirin for 12 weeks in patients with genotype 2 HCV infection.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Gilead Sciences’ new drug application is supported by positive outcome from a Japanese Phase III clinical study (Study GS-US-334-0118) among 153 treatment-naive and treatment-experienced genotype 2 patients.

The company’s application is also supported by sustained virologic response 12 weeks after completing therapy (SVR12) results from four international Phase III studies (FISSION, FUSION, POSITRON and VALENCE), which included genotype 2 HCV patients.

"We believe that sofosbuvir has the potential to provide high cure rates among genotype 2 patients in just 12 weeks of interferon-free therapy."

A second Japanese Phase III clinical trial (Study GS-US-337-0113) has also been conducted by the company. The Phase III study is evaluating a once-daily fixed-dose combination of sofosbuvir 400mg and the NS5A inhibitor ledipasvir 90mg, with and without ribavirin, for treatment of genotype 1 HCV infected patients.

See Also:

Gilead Sciences reported SVR12 results from the study that took place this month. The company plans to file for approval of the ledipasvir/sofosbuvir combination in Japan in the second half this year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Gilead Sciences chief scientific officer and research and development executive vice-president Norbert Bischofberger said: "Based on Phase III studies, we believe that sofosbuvir has the potential to provide high cure rates among genotype 2 patients in just 12 weeks of interferon-free therapy.

According to Gilead Sciences, sofosbuvir represents its first drug application in Japan. The company claims that if approved, sofosbuvir would be the first all-oral treatment regimen for patients in Japan with genotype 2 HCV.

Sofosbuvir is an investigational product in Japan and its safety and efficacy has not yet been established.

Image: Illustration of heppatitis virus. Photo: courtesy of freedigitalphotos.net.